Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NXG6
UPID:
P4HTM_HUMAN
Alternative names:
Hypoxia-inducible factor prolyl hydroxylase 4
Alternative UPACC:
Q9NXG6; Q6PAG6; Q8TCJ9; Q8WV55; Q96F22; Q9BW77
Background:
Transmembrane prolyl 4-hydroxylase, also known as Hypoxia-inducible factor prolyl hydroxylase 4, plays a pivotal role in oxygen sensing within cells. It catalyzes the formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins, targeting HIF1A at 'Pro-402' and 'Pro-564'. This enzyme may act as a cellular oxygen sensor, facilitating the degradation of HIF under normoxic conditions via the von Hippel-Lindau ubiquitination complex.
Therapeutic significance:
The enzyme's involvement in a neurodevelopmental disorder characterized by hypotonia, hyperventilation, impaired intellectual development, and other symptoms underscores its therapeutic significance. Understanding the role of Transmembrane prolyl 4-hydroxylase could open doors to potential therapeutic strategies for treating this complex condition.